Publications by authors named "M Burotto"

Claim this Profile
F
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
R J Motzer, B Escudier, M Burotto, T Powles, A B Apolo

Ann Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.
A Arance, M-A Berciano-Guerrero, J Guo, M S Carlino, P A Ascierto, M Burotto

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy-Related Pancreatitis: A Case Series of 8 Patients from a High-Volume Oncology Centre.
Tomás San Martín, Jaime González-Montero, Alberto Espino, Carlos Rojas, Mauricio Burotto

Case Rep Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sidedness matters: Colon cancer outcomes in low-resource settings.
Jaime González-Montero, Guillermo Valenzuela, Carlos I Rojas, Mauricio Burotto

World J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee.
Jennifer Dent, Micaella Jorge, Nora Sobrevilla, Thomas S Uldrick, Innocent Adoubi, Mauricio Burotto

J Immunother Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis